+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuropathic Pain Drug Market - Global Forecast 2026-2032- Product Image
Neuropathic Pain Drug Market - Global Forecast 2026-2032- Product Image
Sale

Neuropathic Pain Drug Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968619
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neuropathic Pain Drug Market is projected to reach USD 7.36 Billion in 2026. It is expected to continue growing at a CAGR of 8.10%, reaching USD 11.95 Billion by 2032.

Neuropathic pain drug development is moving from broad symptomatic management toward precision-oriented therapies that address diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, spinal cord injury pain, trigeminal neuralgia, radiculopathy, and other nerve-injury syndromes. Epidemiological literature commonly estimates neuropathic pain prevalence at approximately 7% to 10% of the general population, making it a major clinical and economic burden for health systems, payers, and life sciences organizations.

Current treatment is anchored by guideline-supported options such as gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, topical lidocaine, and high-concentration capsaicin, while opioids are increasingly restricted because of safety, dependency, and policy concerns. For pharmaceutical innovators, this creates a clear opportunity for differentiated neuropathic pain medications with improved tolerability, faster onset, disease-specific efficacy, lower discontinuation, and evidence suitable for value-based reimbursement.

Transformative Shifts in the Neuropathic Pain Landscape

The neuropathic pain drug landscape is being reshaped by the rising prevalence of diabetes, cancer survivorship, aging populations, and nerve injury associated with surgery, trauma, infections, and autoimmune disorders. The International Diabetes Federation reported 537 million adults living with diabetes in 2021, with projections rising to 643 million by 2030 and 783 million by 2045, supporting sustained clinical need for diabetic peripheral neuropathy therapies.

At the same time, clinical practice is moving away from one-size-fits-all analgesia. Regulators and payers increasingly expect robust patient-reported outcomes, functional improvement, comparative effectiveness, and safety evidence. Pipeline strategies are therefore prioritizing non-opioid mechanisms, sodium channel modulation, calcium channel modulation, neuroinflammation pathways, cannabinoid-related approaches where permitted, and combination regimens that can address heterogeneous neuropathic pain biology.

Cumulative Impact of Artificial Intelligence in Neuropathic Pain Drug Development

Artificial intelligence is cumulatively improving neuropathic pain drug discovery by accelerating target identification, compound screening, translational biomarker analysis, and clinical trial feasibility. AI-enabled natural language processing can analyze electronic health records to identify underdiagnosed neuropathic pain cohorts, while machine learning models can help stratify patients by symptom cluster, comorbidity, prior medication response, polypharmacy risk, and likelihood of treatment discontinuation.

The greatest near-term value is expected in trial design, pharmacovigilance, and real-world evidence generation rather than fully autonomous drug discovery. AI can support adaptive recruitment, detect safety signals earlier, and integrate wearable, claims, imaging, omics, and patient-reported data. For industry leaders, governance remains essential because pain outcomes are subjective, datasets can be biased, and regulatory acceptance requires transparency, validation, auditability, and reproducibility.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is one of the most dynamic demand centers because China, India, Japan, South Korea, and Australia combine large diabetes populations, aging demographics, expanding pain specialty care, and growing access to branded generics and innovative medicines. Japan and Australia have mature reimbursement systems and stronger clinical guideline adoption, while China and India offer substantial patient-volume potential but require localized pricing, evidence generation, physician education, and distribution strategies.

North America remains the most commercially advanced region, led by the United States and Canada, where established diagnosis pathways, specialist networks, payer scrutiny, and opioid-sparing policies favor evidence-backed non-opioid neuropathic pain drugs. Latin America is gaining relevance as Brazil and Mexico expand diabetes management and private healthcare access, although affordability and formulary inclusion remain central to uptake.

Europe benefits from strong clinical research infrastructure, centralized regulatory pathways, and widespread use of health technology assessment, but access varies by country-level reimbursement criteria and cost-effectiveness thresholds. The Middle East, particularly high-income Gulf health systems, is shaped by significant diabetes and obesity burdens, investment in specialty care, and tender-led procurement. Africa represents a longer-term access opportunity, where underdiagnosis, limited pain specialist availability, medicine affordability, and primary-care capacity influence the adoption of neuropathic pain therapies.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are gaining relevance as diabetes prevalence rises and access to neurology, endocrinology, and pain management services expands in urban centers. Entry strategies are strongest where organizations combine physician education, affordable formulations, pharmacovigilance readiness, and local distributor partnerships. The GCC presents a high-priority opportunity because diabetes and obesity burdens are significant, health systems are investing in specialty care, and branded medicines can gain traction when supported by clinical evidence, tender readiness, and compliant local registration strategies.

The European Union offers scale through harmonized regulatory science and established clinical guidance, but country-specific reimbursement remains decisive for patient access. BRICS countries provide large patient pools, expanding clinical trial activity, and manufacturing advantages, particularly in China, India, and Brazil, yet pricing pressure and procurement requirements are intense. G7 markets remain innovation leaders with strong clinical trial capacity, advanced pharmacovigilance systems, and high evidentiary expectations. NATO-aligned markets overlap substantially with North America and Europe, where supply-chain resilience, secure health data infrastructure, medicine availability, and regulatory alignment are increasingly strategic priorities for neuropathic pain drug commercialization.

Key Country Insights Across Major Neuropathic Pain Drug Markets

The United States is the anchor country for neuropathic pain drug commercialization because of its large diagnosed diabetes population, specialty prescribing base, established clinical trial ecosystem, and strong demand for opioid-sparing pain therapies, though payer controls, prior authorization, and step therapy can limit premium uptake. Canada offers stable reimbursement pathways and guideline-driven care, while Mexico provides growing access opportunities supported by expanding diabetes management, private healthcare demand, and broader use of branded generics. Brazil is a major Latin American opportunity due to its large chronic disease burden and mixed public-private healthcare system, where pricing, local evidence, and formulary access are decisive.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with rigorous reimbursement assessment; Germany is particularly important for early benefit evaluation, while the United Kingdom emphasizes cost-effectiveness through national health technology appraisal. France, Italy, and Spain require strong clinical differentiation and budget-impact evidence, while Russia remains a complex access market shaped by localization, procurement dynamics, and regulatory requirements.

In Asia-Pacific, China and India offer the largest patient-volume opportunities because of diabetes burden, aging populations, and expanding healthcare access, but pricing, local data, and distribution depth are critical. Japan and South Korea provide high-value innovation markets with advanced clinical practice, aging demographics, and strong expectations for quality and safety evidence. Australia supports evidence-based adoption through structured reimbursement, specialist-led care, and clear payer scrutiny, making it important for therapies that can demonstrate clinically meaningful functional and quality-of-life benefits.

Actionable Recommendations for Neuropathic Pain Drug Leaders

Industry leaders should prioritize differentiated clinical profiles, not incremental claims. Development programs need to demonstrate meaningful pain reduction, sleep and function improvement, tolerability, reduced discontinuation, and applicability to defined neuropathic pain subtypes. Strong evidence in diabetic peripheral neuropathy and postherpetic neuralgia remains commercially important, while chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, spinal cord injury pain, and other underserved conditions can support lifecycle expansion.

Commercial teams should align trial endpoints with payer expectations, build real-world evidence early, and prepare country-specific value dossiers. Organizations should also invest in AI-enabled patient identification, pharmacovigilance, adherence analytics, and digital outcome capture while maintaining rigorous data governance. Regional strategies should balance premium launches in G7 markets with affordable access models, branded generics, and partnerships in BRICS, ASEAN, Latin America, the Middle East, and Africa.

Research Methodology

This executive summary is based on secondary research from peer-reviewed neuropathic pain literature, clinical guidelines, regulatory labels, public health datasets, and recognized institutional sources, including international pain associations, diabetes federations, public health agencies, medicines regulators, and national health technology assessment bodies.

The methodology integrates epidemiology, approved treatment standards, pipeline direction, reimbursement dynamics, regional access conditions, artificial intelligence adoption, and technology-enabled evidence generation trends. Insights were triangulated across clinical, regulatory, commercial, and health-system evidence to avoid unsupported market claims and to provide practical intelligence for drug developers, investors, and commercialization teams.

Conclusion

The neuropathic pain drug market is positioned for sustained strategic importance as diabetes, aging, cancer survivorship, neurological disorders, and opioid-sparing treatment policies expand the need for safer and more effective therapies. While existing medicines remain essential, unmet needs persist in efficacy durability, tolerability, patient stratification, treatment adherence, and condition-specific evidence.

Organizations that combine differentiated non-opioid mechanisms, AI-supported development, robust real-world evidence, and localized market access strategies will be best placed to compete. Success will depend on proving value not only through pain score improvement but also through measurable gains in function, sleep, adherence, safety, quality of life, and health-system efficiency.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Neuropathic Pain Drug Market, by Product Type
7.1. Introduction
7.2. Anticonvulsants
7.2.1. Carbamazepine
7.2.2. Gabapentin
7.2.3. Lamotrigine
7.2.4. Pregabalin
7.3. Antidepressants
7.3.1. SNRIs
7.3.1.1. Duloxetine
7.3.1.2. Venlafaxine
7.3.2. TCAs
7.3.2.1. Amitriptyline
7.3.2.2. Nortriptyline
7.4. Opioids
7.4.1. Tapentadol
7.4.2. Tramadol
7.5. Topical Agents
7.5.1. Capsaicin
7.5.2. Diclofenac Gel
7.5.3. Lidocaine Patch
8. Neuropathic Pain Drug Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Topical
8.5. Transdermal
9. Neuropathic Pain Drug Market, by Indication
9.1. Introduction
9.2. Chemotherapy-Induced Neuropathy
9.3. Diabetic Neuropathy
9.4. HIV-Associated Neuropathy
9.5. Post-Herpetic Neuralgia
10. Neuropathic Pain Drug Market, by Distribution Channel
10.1. Introduction
10.2. Hospitals Pharmacy
10.3. Retail Pharmacies
10.4. Specialty Clinics
11. Neuropathic Pain Drug Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Neuropathic Pain Drug Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Neuropathic Pain Drug Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AcelRx Therapeutics, Inc.
15.2. Bausch Health Companies Inc.
15.3. Eli Lilly and Company
15.4. Endo International plc
15.5. Grünenthal GmbH
15.6. Hikma Pharmaceuticals PLC
15.7. Mylan N.V.
15.8. Novartis AG
15.9. Pfizer Inc.
15.10. Sanofi S.A.
15.11. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CARBAMAZEPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CARBAMAZEPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CARBAMAZEPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL LAMOTRIGINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL LAMOTRIGINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL LAMOTRIGINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PREGABALIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SNRIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SNRIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SNRIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL DULOXETINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL DULOXETINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL DULOXETINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL VENLAFAXINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL VENLAFAXINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL VENLAFAXINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TCAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TCAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TCAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL AMITRIPTYLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL AMITRIPTYLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL AMITRIPTYLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NORTRIPTYLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL NORTRIPTYLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL NORTRIPTYLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TAPENTADOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL TAPENTADOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL TAPENTADOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL TRAMADOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TRAMADOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TRAMADOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TOPICAL AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TOPICAL AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TOPICAL AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CAPSAICIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CAPSAICIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CAPSAICIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL DICLOFENAC GEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL DICLOFENAC GEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL DICLOFENAC GEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL LIDOCAINE PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL LIDOCAINE PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL LIDOCAINE PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CHEMOTHERAPY-INDUCED NEUROPATHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CHEMOTHERAPY-INDUCED NEUROPATHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CHEMOTHERAPY-INDUCED NEUROPATHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL DIABETIC NEUROPATHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HIV-ASSOCIATED NEUROPATHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HIV-ASSOCIATED NEUROPATHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HIV-ASSOCIATED NEUROPATHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL POST-HERPETIC NEURALGIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL POST-HERPETIC NEURALGIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL POST-HERPETIC NEURALGIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITALS PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 133. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 134. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 135. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 136. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 137. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 138. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 139. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 141. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 153. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 155. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 156. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 157. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 158. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 159. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 160. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 161. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 163. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 167. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 168. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 169. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 170. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 171. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 172. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 173. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 175. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 178. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 179. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 180. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 181. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 182. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 183. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 184. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 186. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 200. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 201. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 202. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 203. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 204. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 205. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 206. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 208. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 210. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 211. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 212. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 213. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 214. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 215. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 216. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 217. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 219. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 222. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 223. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 224. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 225. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 226. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 227. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 228. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 230. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 245. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 246. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 247. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 248. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 249. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 250. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 251. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 253. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 256. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 257. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 258. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 259. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 260. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 261. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 262. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 264. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 289. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 290. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 291. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 292. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 293. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 294. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 295. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 297. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 298. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 300. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 301. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 302. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 303. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 304. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 305. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 306. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 308. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 311. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 312. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 313. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 314. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 315. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 316. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 319. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 320. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 322. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 323. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 324. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 325. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 326. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 327. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 328. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 330. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 331. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 332. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 333. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 334. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 335. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 336. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 337. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 338. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 339. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 341. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 342. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 343. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 344. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 345. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 346. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 347. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 348. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 349. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 350. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 351. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 352. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 353. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 354. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 355. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2017-2032 (USD MILLION)
TABLE 356. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2017-2032 (USD MILLION)
TABLE 357. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2017-2032 (USD MILLION)
TABLE 358. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2017-2032 (USD MILLION)
TABLE 359. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 360. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2017-2032 (USD MILLION)
TABLE 361. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 362. INDIA NEUROPATHIC PAI

Companies Mentioned

  • AcelRx Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Grünenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.36 Billion
Forecasted Market Value ( USD ) by 2032 $ 11.95 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Peripheral Neuropathic Pain Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Application, Distribution Channel, and Region, 2025-2035 - Product Image

Peripheral Neuropathic Pain Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Application, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From
Neuropathic Pain Market Size, Share & Trends Analysis Report by Drug Class,, Indication, Route of Administration, Distribution Channel, Region, and Growth Forecasts, 2026-2033 - Product Image

Neuropathic Pain Market Size, Share & Trends Analysis Report by Drug Class,, Indication, Route of Administration, Distribution Channel, Region, and Growth Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Neuropathic Pain Market - Global Strategic Business Report - Product Image

Neuropathic Pain Market - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Neuropathic Pain - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Neuropathic Pain - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Diabetic Neuropathic Pain Market - A Global and Regional Analysis: Focus on Type, Distribution Channel, and Region, 2025-2035 - Product Image

Diabetic Neuropathic Pain Market - A Global and Regional Analysis: Focus on Type, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From

About the Neuropathic Pain Drug Market

The Neuropathic Pain Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neuropathic pain drugs are used to treat chronic pain caused by nerve damage, such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. These drugs are typically divided into two categories: anticonvulsants and antidepressants. Anticonvulsants are used to reduce the intensity of nerve pain, while antidepressants are used to reduce the frequency of nerve pain. Commonly prescribed neuropathic pain drugs include pregabalin, gabapentin, duloxetine, and amitriptyline. Some companies in the Neuropathic Pain Drug market include Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.